{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-277662","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.968633+00:00","generated_at":"2026-05-16T21:37:58.725756+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AN2 Therapeutics Q3 2025 net loss $9.4M, cash $65.1M; Chagas Phase 1 ongoing","bullets":["Net loss of $9.4M vs $12.7M in Q3 2024, R&D expense $7.0M (down from $8.3M), G&A $3.0M.","Cash, equivalents and investments $65.1M at Sept 30, 2025; projected runway into 2028.","Chagas Phase 1 of oral AN2-502998 advancing; data expected Q1 2026, Phase 2 start in 2026.","M. abscessus program: IIT expected to begin enrollment early 2026, pending regulatory clearance.","Collaboration with GSK on boron-based TB drugs, with third-year Gates Foundation funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-277662","json":"https://secwatch.observer/filing/0001193125-25-277662.json","markdown":"https://secwatch.observer/filing/0001193125-25-277662.md","text":"https://secwatch.observer/filing/0001193125-25-277662.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/0001193125-25-277662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/antx-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:37:58.725756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}